Inquiry Basket
Loading ......
Metabolic syndrome (MetS) is a cluster of metabolic abnormalities that commonly includes central obesity, elevated blood pressure, impaired glucose regulation, and abnormal lipid profiles. Beyond its established association with cardiovascular disease and type 2 diabetes, MetS is also characterized by chronic low-grade inflammation and altered immune regulation. At the same time, low circulating 25-hydroxyvitamin D [25(OH)D] concentrations are frequently observed in individuals with metabolic syndrome. However, understanding this relationship requires more than measuring total serum vitamin D. Obesity, vitamin D-binding protein, genetic variation, tissue sequestration, and vitamin D metabolism can all influence how much vitamin D is biologically available to cells. These factors make 25-OH vitamin D bioavailability an important consideration when examining the relationship between vitamin D status, metabolic dysfunction, and immune regulation.
25(OH)D is the major circulating form of vitamin D and is widely used to evaluate vitamin D status. Multiple observational studies have reported lower 25(OH)D concentrations in individuals with metabolic syndrome compared with metabolically healthier populations. In one reported comparison, mean 25(OH)D concentrations were approximately 41.90 ± 13.12 nmol/L among individuals with MetS compared with 66.09 ± 18.02 nmol/L in those without MetS, while 25(OH)D concentrations tended to decrease as the number of metabolic syndrome diagnostic components increased. This pattern suggests that vitamin D status may be related to overall metabolic burden rather than a single abnormality such as elevated glucose or blood pressure. However, low vitamin D may also reflect the metabolic environment itself, because obesity, reduced outdoor activity, dietary patterns, altered vitamin D metabolism, and differences in body composition can all contribute to lower circulating 25(OH)D. Therefore, the observed association between low vitamin D status and metabolic syndrome should not automatically be interpreted as evidence that vitamin D deficiency directly causes MetS.
The biological availability of vitamin D depends not only on its total circulating concentration but also on how vitamin D metabolites are transported, bound, metabolized, and delivered to target tissues. Most circulating vitamin D metabolites are bound to vitamin D-binding protein (VDBP) and albumin, whereas only a relatively small fraction circulates in a free form. Free and albumin-bound fractions are often considered when estimating the potentially bioavailable vitamin D pool. This distinction becomes particularly relevant in obesity and metabolic syndrome because vitamin D is fat-soluble and can become distributed or sequestered within adipose tissue, potentially altering the relationship between circulating 25(OH)D and tissue availability. Genetic variation in VDBP, vitamin D-metabolizing enzymes, transport proteins, or the vitamin D receptor (VDR) can further influence vitamin D pharmacokinetics and cellular responsiveness. Consequently, individuals with similar total serum 25(OH)D concentrations may not necessarily have identical biologically available vitamin D or equivalent biological responses.
The immune system is closely integrated with metabolic health, and excess adipose tissue can contribute to persistent production of inflammatory mediators that sustain a low-grade inflammatory environment. Vitamin D participates in this immune-metabolic network through VDR-mediated signaling and local vitamin D metabolism. Immune cells including monocytes, macrophages, dendritic cells, and lymphocytes can respond to vitamin D signaling, while certain immune cells express CYP27B1, the enzyme that converts 25(OH)D into the biologically active metabolite 1,25-dihydroxyvitamin D [1,25(OH)2D]. This local conversion allows circulating 25(OH)D to function as a substrate for immune-cell signaling. Rather than acting simply as an immune stimulant, vitamin D is better understood as an immune regulator capable of influencing inflammatory signaling, antimicrobial responses, antigen presentation, and lymphocyte activity. This provides a plausible biological connection between vitamin D availability and the chronic inflammatory environment observed in metabolic syndrome.
One of the most studied aspects of vitamin D immunobiology is its influence on T-cell differentiation and activity. Active vitamin D signaling through VDR can reduce excessive Th1- and Th17-associated inflammatory responses under appropriate experimental conditions while favoring regulatory T-cell activity and immune tolerance. These effects are potentially relevant to metabolic syndrome because chronic low-grade inflammation involves interactions among adipocytes, macrophages, cytokines, and adaptive immune cells. Vitamin D signaling may therefore help regulate the balance between inflammatory and regulatory immune responses rather than simply suppressing immunity. Vitamin D can also influence B-cell proliferation, differentiation, and antibody-related responses, suggesting effects across both cellular and humoral immunity. Nevertheless, many mechanistic findings originate from cellular or experimental models, and their biological plausibility does not by itself demonstrate that increasing serum 25(OH)D in humans will reverse inflammation or prevent metabolic syndrome.
Human intervention studies provide a more cautious but informative perspective. A prospective study involving 44 individuals with metabolic syndrome reported that weekly supplementation with 50,000 IU vitamin D for six weeks was associated with reductions in systolic blood pressure, diastolic blood pressure, and IL-12 concentrations. Participants who achieved 25(OH)D concentrations of at least 32 ng/mL also had lower IL-12 levels than participants whose concentrations remained below 32 ng/mL. These findings are biologically interesting because they suggest that improving vitamin D status may coincide with changes in selected inflammatory and cardiovascular-related parameters. However, the study was relatively small and short, and therefore cannot establish that vitamin D supplementation is responsible for the observed changes or that the findings apply broadly to all individuals with metabolic syndrome. Observational analyses have also reported that higher 25(OH)D concentrations are associated with a lower likelihood of MetS, with some analyses estimating that each 10 ng/mL increase in 25(OH)D may correspond to approximately a 15-20% lower risk of metabolic syndrome, but potential confounding factors mean these associations should not be interpreted as proof of causality.
For individuals with metabolic syndrome, total serum 25(OH)D may not fully capture the biological context of vitamin D exposure. Because adipose tissue can serve as a storage compartment for fat-soluble vitamin D, increased adiposity may alter vitamin D distribution and the relationship between circulating concentrations and tissue availability. At the same time, VDBP concentrations do not necessarily differ substantially between individuals with and without metabolic syndrome in every study, indicating that differences in free or bioavailable vitamin D cannot simply be attributed to changes in VDBP levels. The interaction among adiposity, VDBP, albumin, vitamin D metabolism, and VDR signaling is therefore considerably more complex than a simple model in which low serum 25(OH)D directly indicates low cellular vitamin D exposure. This complexity is particularly important when comparing vitamin D status across metabolically diverse populations or evaluating whether supplementation changes biologically relevant vitamin D availability.
Serum 25(OH)D remains the principal laboratory marker for evaluating vitamin D status because it reflects vitamin D exposure and has a longer circulating half-life than the active hormone 1,25(OH)2D. For individuals at risk of vitamin D deficiency, serum 25(OH)D can therefore provide useful information about overall vitamin D status. Measurements of free 25(OH)D, bioavailable 25(OH)D, and VDBP may provide additional information in selected research settings or populations in which differences in vitamin D binding could substantially affect interpretation, although these measurements are not interchangeable with conventional total 25(OH)D testing and their clinical usefulness depends on the population, assay methodology, and specific research question. In metabolic syndrome research, evaluating several components of vitamin D status may help distinguish changes in total circulating vitamin D from differences in protein binding, bioavailability, or tissue distribution.
Because low vitamin D status frequently occurs alongside obesity, hypertension, insulin resistance, dyslipidemia, and systemic inflammation, it is tempting to assume that correcting vitamin D deficiency will directly reduce cardiovascular risk. However, the available evidence does not support such a simple conclusion. Although several biological mechanisms could potentially connect vitamin D signaling with vascular function, inflammation, and metabolic health, clinical evidence has not established vitamin D supplementation as a general cardiovascular-protective treatment. Current endocrine guidance has emphasized that the available evidence is insufficient to prescribe vitamin D specifically to obtain cardiovascular protection. This distinction is important: correcting documented vitamin D deficiency is not equivalent to prescribing vitamin D as a cardiovascular therapy, and evidence supporting one does not automatically establish the other.
The relationship between vitamin D and metabolic syndrome is best understood as a multidimensional interaction involving metabolism, body composition, vitamin D transport, immune signaling, and lifestyle. Low 25(OH)D concentrations are commonly associated with metabolic syndrome and may decline as the overall metabolic burden increases, while obesity can modify vitamin D distribution and potentially its biological availability. At the cellular level, vitamin D signaling can influence macrophages, dendritic cells, T cells, and B cells and can modulate inflammatory and regulatory immune pathways. Nevertheless, these observations do not establish a simple causal pathway in which vitamin D deficiency drives metabolic syndrome or supplementation reverses it. An increase in circulating 25(OH)D following supplementation also does not necessarily mean that immune or metabolic outcomes will improve, highlighting why vitamin D bioavailability and tissue-level signaling deserve greater attention.
Future studies examining vitamin D and metabolic syndrome may benefit from integrating vitamin D status with measurements of adiposity, metabolic dysfunction, inflammatory signaling, and immune-cell behavior. Assessing total 25(OH)D together with free or bioavailable vitamin D may help clarify whether apparent differences in vitamin D status reflect changes in circulating concentration, protein binding, or tissue distribution, while VDBP and vitamin D-metabolizing enzymes can provide additional mechanistic information. Longitudinal and randomized intervention studies are particularly important for distinguishing temporal associations from potential causal effects. Factors such as body mass index, waist circumference, physical activity, dietary intake, season, sunlight exposure, kidney and liver function, and medication use should also be considered because they can influence both vitamin D status and metabolic health. A more comprehensive assessment may ultimately provide a clearer understanding of whether vitamin D availability is simply a marker of metabolic health or an independently modifiable component of the immune-metabolic environment.
The relationship between 25-OH vitamin D bioavailability and immune function in metabolic syndrome extends well beyond whether an individual's serum 25(OH)D concentration is simply high or low. Low 25(OH)D is frequently associated with metabolic syndrome and appears to correlate with increasing metabolic burden, while obesity and altered vitamin D distribution can complicate the relationship between circulating vitamin D and tissue availability. Vitamin D signaling also interacts with innate and adaptive immune pathways, including macrophage activity, inflammatory T-cell responses, regulatory T-cell function, and B-cell behavior. Human intervention findings provide potentially important signals but remain insufficient to establish vitamin D supplementation as a treatment for metabolic syndrome or as a strategy for cardiovascular protection. For clinical and research applications, serum 25(OH)D remains the primary measure of vitamin D status, while free and bioavailable vitamin D measurements may provide additional insight in appropriately selected populations and study designs. The most informative perspective is therefore to consider vitamin D availability, metabolism, and signaling within the broader metabolic and inflammatory environment, rather than interpreting a single serum measurement in isolation.
Low serum 25(OH)D concentrations are frequently associated with metabolic syndrome and may decrease as the number of metabolic abnormalities increases. However, most available evidence is observational, so low vitamin D status should not be interpreted as a proven direct cause of metabolic syndrome.
Vitamin D bioavailability can be influenced by obesity, adipose tissue distribution, VDBP binding, albumin, genetic variation, and vitamin D metabolism. As a result, total serum 25(OH)D may not always fully reflect the fraction of vitamin D that is potentially available to tissues and immune cells.
Vitamin D signaling through the vitamin D receptor (VDR) can regulate both innate and adaptive immune responses. Active vitamin D can influence macrophages, dendritic cells, T cells, and B cells and may help moderate excessive Th1- and Th17-associated inflammatory activity while supporting regulatory immune pathways.
Some intervention studies have reported improvements in selected parameters, such as blood pressure or inflammatory markers, following vitamin D supplementation. However, the evidence remains insufficient to conclude that vitamin D supplementation directly treats metabolic syndrome, particularly because many studies are small, short-term, or observational.
Serum total 25(OH)D remains the primary marker used to assess vitamin D status, but free or bioavailable 25(OH)D and VDBP measurements may provide additional information in selected research populations. Their interpretation depends on the population, assay methodology, and specific clinical or research objective.
References
| Target | Cat. No. | Product Name | Host | Application | |
| 25-OH Vitamin D | DMABA-JX119 | Rabbit Anti-25 OH Vitamin D monoclonal antibody, clone S594L4 | Rabbit | ELISA, LFIA, CLIA | Inquiry |
| DMABA-JX120 | Rabbit Anti-25 OH Vitamin D monoclonal antibody, clone S595K5 | Rabbit | ELISA, LFIA, CLIA | Inquiry | |
| DMAB-JXL2399 | Goat Anti-25-OH VD2/VD3 Monoclonal Antibody, clone 5C3 | CHO | ELISA, CLIA, LFIA | Inquiry | |
| DMAB2913 | Mouse Anti-25 OH Vitamin D3 monoclonal antibody, clone L35235N | Mouse | ELISA | Inquiry | |
| DMAB2914 | Mouse Anti-25 OH Vitamin D3 Monoclonal antibody, clone C2531M | Mouse | ELISA | Inquiry | |
| CABT-L1343W | Humanized Anti-Human 25-OH-VD Monoclonal antibody, clone 214I2T | Humanized | LFIA, CLIA | Inquiry | |
| CABT-L1344W | Humanized Anti-Human 25-OH-VD Monoclonal antibody, clone 214I5 | Humanized | PETIA | Inquiry |
| Target | Cat. No. | Product Name | Conjugate | Application | |
| 25-OH Vitamin D | DAG-WT2678 | 25-hydroxyvitamin D control | Unconjugated | Calibration, Control | Inquiry |
| DAG-WT2679 | 25-hydroxyvitamin D2 control | Unconjugated | Calibration, Control | Inquiry | |
| DAG-WT2680 | 25-hydroxyvitamin D3 control | Unconjugated | Calibration, Control | Inquiry | |
| DAG03219 | 25-OH Vitamin D3 [BSA] | BSA | ELISA, LFIA | Inquiry | |
| DAGA-126H | 25-OH Vitamin D [HRP] | HRP | ELISA | Inquiry | |
| DAGA-126K | 25-OH Vitamin D [KLH] | KLH | Immunogen | Inquiry | |
| DAG-WT6032B | 25-OH Vitamin D2 [BSA] | BSA | ELISA, LFIA | Inquiry |
| Target | Cat. No. | Product Name | Species Reactivity | Application | Detection Sample | |
| 25-OH Vitamin D | DEIA4458 | 25-OH Vitamin D ELISA Kit | Human | Quantitative | Serum, Plasma | Inquiry |
| DEIA1733 | 25 (OH) Vitamin D ELISA Kit | Human | Quantitative | plasma, serum | Inquiry | |
| DEIA002J | 25-OH Vitamin D direct (1-point calibration) ELISA Kit | Human | Quantitative | serum | Inquiry | |
| DEIA003J | 25-OH Vitamin D direct day ELISA Kit | Human | Quantitative | serum, fresh plasma | Inquiry | |
| DEIA004J | 25-OH Vitamin D direct ELISA Kit | Human | Quantitative | serum, fresh plasma | Inquiry | |
| DEIA005J | 25-OH Vitamin D Xpress ELISA Kit | Human | Quantitative | serum, fresh EDTA plasma | Inquiry | |
| DEIA006J | 25-OH Vitamin D ELISA Kit | Human | Quantitative | serum, plasma | Inquiry | |
| DEIA2219 | 25-OH Vitamin D (total) ELISA Kit | Human | Quantitative | Serum | Inquiry | |
| DEIA-BJ574-1 | Human 25 (OH) D3 ELISA kit | Human | Quantitative | Serum, plasma and other biological fluids. | Inquiry | |
| DEIA-BJ2145 | Rat 25 Hydroxy Vitamin D3 ELISA Kit | Rat | Quantitative | Serum, plasma, cell culture supernatants, body fluid and tissue homogenate | Inquiry | |
| DEIA-NS2651 | 25OH-D (Total 25-OH Vitamin D) ELISA Kit | Universal | Quantitative | Serum, plasma, cellculture supernatant and other biological samples. | Inquiry | |
| DEIA-BJ648 | Human 25 Hydroxy Vitamin D ELISA kit | Human | Quantitative | biological fluids. | Inquiry |
Loading ......
